Browse through all publications from the Institute of Global Health Innovation, which our Patient Safety Research Collaboration is part of. This feed includes reports and research papers from our Centre. 

Citation

BibTex format

@article{Smith:2026:10.1016/S2215-0366(26)00228-2,
author = {Smith, KA and Siafis, S and McCutcheon, RA and Pillinger, T and Upthegrove, R and Downs, J and Seedat, S and Lawrance, EL and Salanti, G and Gureje, O and Singh, I and Potts, J and Teferra, S and Sartor, C and Mudenge, C and Correll, CU and Cipriani, A},
doi = {10.1016/S2215-0366(26)00228-2},
journal = {Lancet Psychiatry},
pages = {884--896},
title = {Improving access to antipsychotic medications for schizophrenia in Ethiopia, Nigeria, Rwanda, and South Africa: an evidence-based global consensus.},
url = {http://dx.doi.org/10.1016/S2215-0366(26)00228-2},
volume = {13},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - There are disparities in access to antipsychotics for schizophrenia across different country settings. Improving access to a wider and more equitable range of medications in low-income and middle-income countries is a priority. A multidisciplinary team of international experts, including individuals with lived experience, appraised the most relevant and recent information on antipsychotics in schizophrenia and contextualised it to four African countries (Ethiopia, Nigeria, Rwanda, and South Africa) using a validated consensus methodology. We recommended a list of drugs to prioritise to guide clinical implementation and research, and market shaping. We identified key evidence gaps: little of the existing evidence comes from the countries of interest, trials generally involve highly selected populations, and the complexity of real-world settings is not reflected. However, this methodology highlights a route forward to prioritise the best available evidence on pharmacological treatments for schizophrenia at a global scale, which could also be applied to treatments for other mental health conditions.
AU  - Smith,KA
AU  - Siafis,S
AU  - McCutcheon,RA
AU  - Pillinger,T
AU  - Upthegrove,R
AU  - Downs,J
AU  - Seedat,S
AU  - Lawrance,EL
AU  - Salanti,G
AU  - Gureje,O
AU  - Singh,I
AU  - Potts,J
AU  - Teferra,S
AU  - Sartor,C
AU  - Mudenge,C
AU  - Correll,CU
AU  - Cipriani,A
DO  - 10.1016/S2215-0366(26)00228-2
EP  - 896
PY  - 2026///
SP  - 884
TI  - Improving access to antipsychotic medications for schizophrenia in Ethiopia, Nigeria, Rwanda, and South Africa: an evidence-based global consensus.
T2  - Lancet Psychiatry
UR  - http://dx.doi.org/10.1016/S2215-0366(26)00228-2
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42716058
VL  - 13
ER  -
Download